bluebird bio Inc. | Mutual Funds
Mutual Funds that own bluebird bio Inc.
American Funds Growth Fund of America
3,569,336
6.59%
683,020
0.33%
06/30/2018
Fidelity Growth Company Fund
2,677,813
4.94%
88,124
0.93%
07/31/2018
American Funds Small Cap World Fund
2,106,520
3.89%
0
0.93%
06/30/2018
American Funds New Economy Fund
1,442,514
2.66%
-666,620
1.26%
06/30/2018
Vanguard Small Cap Index Fund
1,346,292
2.49%
101,469
0.23%
07/31/2018
Vanguard Total Stock Market Index Fund
1,344,821
2.48%
93,412
0.03%
07/31/2018
Scottish Mortgage Investment Trust Plc
942,640
1.74%
0
1.58%
10/31/2017
T Rowe Price Health Sciences Fund
932,281
1.72%
61,900
1.23%
06/30/2018
Vanguard Small Cap Growth Index Fund
768,590
1.42%
59,306
0.5%
07/31/2018
Fidelity Series Growth Company Fund
762,465
1.41%
28,100
0.96%
07/31/2018
| Address |
60 Binney Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.bluebirdbio.com |
| Updated |
07/08/2019 |
| bluebird bio, Inc. is a clinical-stage biotechnology company. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. It offers the LentiGlobin which is a treatment for transfusion-dependent ß-thalassemia; and Lenti-D as a treatment for cerebral adrenoleukodystrophy. |
